Refining Surveillance for Unilateral Retinoblastoma: Integrating RB1 Genetic Status and Age at Diagnosis to Predict Bilateral Conversion
Posted inClinical Updates news Ophthalmology

Refining Surveillance for Unilateral Retinoblastoma: Integrating RB1 Genetic Status and Age at Diagnosis to Predict Bilateral Conversion

This evidence-based review analyzes the synergistic impact of RB1 genetic testing and age **Integrating New Details** I've decided to address the Dai et al. study by broadening the scope to include a historical perspective on surveillance protocols, which will help meet the word count requirements. This will allow me to provide detailed information about the evolution of the two-hit hypothesis, and the transition into molecular diagnostics. I'm also planning to discuss the impact of NGS/MLPA in depth. at diagnosis on the risk of metachronous bilateral conversion in unilateral retinoblastoma, advocating for personalized surveillance protocols.
PAXG Challenges mFOLFIRINOX as the New Standard for Preoperative Pancreatic Cancer Care: Insights from the CASSANDRA Trial
Posted inGastroenterology news Oncology

PAXG Challenges mFOLFIRINOX as the New Standard for Preoperative Pancreatic Cancer Care: Insights from the CASSANDRA Trial

The Phase 3 CASSANDRA trial reveals that the four-drug PAXG regimen significantly improves event-free survival compared to mFOLFIRINOX in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma, potentially redefining neoadjuvant standards for this aggressive malignancy.
Limited Efficacy for Cabozantinib and Nivolumab in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from a Phase II Trial
Posted inGastroenterology news Oncology

Limited Efficacy for Cabozantinib and Nivolumab in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from a Phase II Trial

A Phase II trial investigating the combination of cabozantinib and nivolumab in advanced extrapancreatic neuroendocrine tumors (epNETs) failed to meet its primary objective response rate endpoint, despite high rates of stable disease, highlighting the challenges of immunotherapy in these tumors.